MX2015011362A - Metodo para el pronostico y tratamiento de metastasis de cancer. - Google Patents
Metodo para el pronostico y tratamiento de metastasis de cancer.Info
- Publication number
- MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- cancer
- bone metastases
- gene
- interest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801718P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2014/001253 WO2014140933A2 (en) | 2013-03-15 | 2014-03-14 | Method for the prognosis and treatment of cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011362A true MX2015011362A (es) | 2015-12-16 |
Family
ID=51265712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011362A MX2015011362A (es) | 2013-03-15 | 2014-03-14 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160032400A1 (enExample) |
| EP (1) | EP2971113B1 (enExample) |
| JP (1) | JP6577873B2 (enExample) |
| KR (1) | KR20150122731A (enExample) |
| CN (1) | CN105324491B (enExample) |
| AU (1) | AU2014229505B2 (enExample) |
| BR (1) | BR112015023783A2 (enExample) |
| CA (1) | CA2906394A1 (enExample) |
| MX (2) | MX2015011362A (enExample) |
| WO (1) | WO2014140933A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| ES3015226T3 (en) | 2012-08-16 | 2025-04-30 | Veracyte Sd Inc | Prostate cancer prognosis using biomarkers |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2888122A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf |
| EP2968988A4 (en) | 2013-03-14 | 2016-11-16 | Allegro Diagnostics Corp | METHOD FOR EVALUATING A COPD STATUS |
| KR20150122786A (ko) | 2013-03-15 | 2015-11-02 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 암 전이의 진단, 예후 및 치료를 위한 방법 |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| CA3015054A1 (en) * | 2016-02-18 | 2017-08-24 | Kyoto University | Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor |
| EP3439640B1 (en) * | 2016-04-08 | 2024-01-17 | The Cleveland Clinic Foundation | Nanoparticles for drug delivery to treat bone disease |
| US20190218302A1 (en) * | 2016-05-19 | 2019-07-18 | Probiocon Gmbh | Anti-cancer combination treatment |
| CA3025264A1 (en) * | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| WO2018013542A1 (en) * | 2016-07-12 | 2018-01-18 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds for use in diagnosing and modeling cancer |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| WO2018132916A1 (en) | 2017-01-20 | 2018-07-26 | Genomedx Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| AU2018230784A1 (en) | 2017-03-09 | 2019-10-10 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2018205035A1 (en) | 2017-05-12 | 2018-11-15 | Genomedx Biosciences, Inc | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
| CA3082728A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN108084254A (zh) * | 2017-11-30 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用 |
| WO2021185959A1 (en) * | 2020-03-19 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases |
| CN115198013B (zh) * | 2021-04-14 | 2026-06-12 | 迪瑞药业(成都)有限公司 | 用以鉴别出适用精氨酸剥夺疗法的患者的方法与试剂盒 |
| EP4662329A1 (en) * | 2023-02-08 | 2025-12-17 | Iogenetics, LLC. | Cleaved neoepitopes |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| ATE497001T1 (de) | 1996-12-23 | 2011-02-15 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| DE60132975T2 (de) | 2000-01-06 | 2009-02-26 | Merck Frosst Canada Inc., Kirkland | Neue substanzen und verbindungen als protease-inhibitoren |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20090246208A1 (en) * | 2006-01-05 | 2009-10-01 | Novartis Ag | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| US8728738B2 (en) * | 2008-07-02 | 2014-05-20 | Assistance Publique-Hopitaux De Paris | Method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| ES2562274T3 (es) * | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
-
2014
- 2014-03-14 US US14/776,412 patent/US20160032400A1/en not_active Abandoned
- 2014-03-14 BR BR112015023783A patent/BR112015023783A2/pt not_active Application Discontinuation
- 2014-03-14 WO PCT/IB2014/001253 patent/WO2014140933A2/en not_active Ceased
- 2014-03-14 KR KR1020157026432A patent/KR20150122731A/ko not_active Ceased
- 2014-03-14 JP JP2015562411A patent/JP6577873B2/ja active Active
- 2014-03-14 CN CN201480015564.0A patent/CN105324491B/zh active Active
- 2014-03-14 CA CA2906394A patent/CA2906394A1/en active Pending
- 2014-03-14 EP EP14747411.8A patent/EP2971113B1/en active Active
- 2014-03-14 AU AU2014229505A patent/AU2014229505B2/en active Active
- 2014-03-14 MX MX2015011362A patent/MX2015011362A/es unknown
-
2015
- 2015-09-02 MX MX2020001156A patent/MX2020001156A/es unknown
-
2021
- 2021-04-27 US US17/241,571 patent/US20210317534A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105324491A (zh) | 2016-02-10 |
| AU2014229505B2 (en) | 2020-02-27 |
| CN105324491B (zh) | 2021-10-26 |
| US20210317534A1 (en) | 2021-10-14 |
| JP2016516403A (ja) | 2016-06-09 |
| KR20150122731A (ko) | 2015-11-02 |
| MX2020001156A (es) | 2020-03-12 |
| WO2014140933A3 (en) | 2014-12-31 |
| JP6577873B2 (ja) | 2019-09-18 |
| WO2014140933A8 (en) | 2020-10-01 |
| EP2971113A2 (en) | 2016-01-20 |
| AU2014229505A1 (en) | 2015-09-03 |
| EP2971113B1 (en) | 2020-08-12 |
| WO2014140933A2 (en) | 2014-09-18 |
| CA2906394A1 (en) | 2014-09-18 |
| US20160032400A1 (en) | 2016-02-04 |
| BR112015023783A2 (pt) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MX2015004610A (es) | Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf. | |
| AR083357A1 (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama | |
| BR112014030750A2 (pt) | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| MX366164B (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| MX2020004567A (es) | Metodos diagnosticos y terapeuticos para el cancer. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| MX2015002749A (es) | Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas. | |
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2018009112A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. | |
| UY31535A1 (es) | Método para diagnosticar tumores colorrectales | |
| UY31534A1 (es) | Metodo para diagnosticar tumores colorrectales | |
| PL402289A1 (pl) | Biomarker molekularny, narzędzie diagnostyczne do określania ryzyka rozwoju chorób układu krążenia, zastosowanie biomarkerów molekularnych | |
| UA95656U (uk) | Спосіб прогнозування зрощення перелому | |
| UA99752U (uk) | Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози | |
| UA95628U (uk) | Спосіб прогнозування зрощення перелому |